Bioscience

TGen Drug Development (TD2) establishes European footprint

November 18, 2009

By Flinn Foundation

[Source: TGen] – TGen Drug Development (TD2) and the Institut Paoli-Calmettes (IPC) have forged a strategic alliance that will enable both to maximize their worldwide contributions in the treatment of cancer patients.

The partnership between TD2, a Scottsdale subsidiary of the Phoenix-based Translational Genomics Research Institute (TGen), and Marseille, France-based IPC’s comprehensive cancer center will enable both non-profit institutes to speed research discoveries to patients with cancer.

For more information: TGen Drug Development (TD2) establishes European footprint